247 related articles for article (PubMed ID: 27444071)
1. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
Lim YH; Ovejero D; Derrick KM; ; Collins MT; Choate KA
J Am Acad Dermatol; 2016 Aug; 75(2):420-7. PubMed ID: 27444071
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Skeletal Hypophosphatemia Syndrome in Association with a Mosaic
Park PG; Park E; Hyun HS; Kang HG; Ha IS; Cho TJ; Ko JM; Cheong HI
Ann Clin Lab Sci; 2018 Sep; 48(5):665-669. PubMed ID: 30373874
[TBL] [Abstract][Full Text] [Related]
3. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.
Lim YH; Ovejero D; Sugarman JS; Deklotz CM; Maruri A; Eichenfield LF; Kelley PK; Jüppner H; Gottschalk M; Tifft CJ; Gafni RI; Boyce AM; Cowen EW; Bhattacharyya N; Guthrie LC; Gahl WA; Golas G; Loring EC; Overton JD; Mane SM; Lifton RP; Levy ML; Collins MT; Choate KA
Hum Mol Genet; 2014 Jan; 23(2):397-407. PubMed ID: 24006476
[TBL] [Abstract][Full Text] [Related]
4. Mosaic NRAS Q61R mutation in a child with giant congenital melanocytic naevus, epidermal naevus syndrome and hypophosphataemic rickets.
Ramesh R; Shaw N; Miles EK; Richard B; Colmenero I; Moss C
Clin Exp Dermatol; 2017 Jan; 42(1):75-79. PubMed ID: 27900779
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.
Ovejero D; Lim YH; Boyce AM; Gafni RI; McCarthy E; Nguyen TA; Eichenfield LF; DeKlotz CM; Guthrie LC; Tosi LL; Thornton PS; Choate KA; Collins MT
Osteoporos Int; 2016 Dec; 27(12):3615-3626. PubMed ID: 27497815
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome.
Carli D; Cardaropoli S; Tessaris D; Coppo P; La Selva R; Cesario C; Lepri FR; Pullano V; Palumbo M; Ramenghi U; Brusco A; Medico E; De Sanctis L; Ferrero GB; Mussa A
Genes Chromosomes Cancer; 2022 Dec; 61(12):740-746. PubMed ID: 35999193
[TBL] [Abstract][Full Text] [Related]
7. Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source.
Ovejero D; Michel Z; Cataisson C; Saikali A; Galisteo R; Yuspa SH; Collins MT; de Castro LF
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36943390
[TBL] [Abstract][Full Text] [Related]
8. Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.
Avitan-Hersh E; Tatur S; Indelman M; Gepstein V; Shreter R; Hershkovitz D; Brick R; Bergman R; Tiosano D
J Clin Endocrinol Metab; 2014 Jan; 99(1):E132-6. PubMed ID: 24243633
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
10. Hypophosphatemic rickets: A rare complication of congenital melanocytic nevus syndrome.
Welfringer-Morin A; Pinto G; Baujat G; Vial Y; Hadj-Rabia S; Bodemer C; Boccara O
Pediatr Dermatol; 2020 May; 37(3):541-544. PubMed ID: 32157705
[TBL] [Abstract][Full Text] [Related]
11. A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome.
Merz LM; Buerger F; Ziegelasch N; Zenker M; Wieland I; Lipek T; Wallborn T; Terliesner N; Prenzel F; Siekmeyer M; Dittrich K
Front Endocrinol (Lausanne); 2022; 13():866831. PubMed ID: 35600592
[TBL] [Abstract][Full Text] [Related]
12. Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report.
Khadora M; Mughal MZ
Bone Rep; 2021 Dec; 15():101138. PubMed ID: 34660853
[TBL] [Abstract][Full Text] [Related]
13. Keratinocytic epidermal nevi associated with localized fibro-osseous lesions without hypophosphatemia.
Mestach L; Polubothu S; Calder A; Denayer E; Gholam K; Legius E; Levtchenko E; Van Laethem A; Brems H; Kinsler VA; Morren MA
Pediatr Dermatol; 2020 Sep; 37(5):890-895. PubMed ID: 32662096
[TBL] [Abstract][Full Text] [Related]
14. Keratinocytic epidermal nevi are associated with mosaic RAS mutations.
Hafner C; Toll A; Gantner S; Mauerer A; Lurkin I; Acquadro F; Fernández-Casado A; Zwarthoff EC; Dietmaier W; Baselga E; Parera E; Vicente A; Casanova A; Cigudosa J; Mentzel T; Pujol RM; Landthaler M; Real FX
J Med Genet; 2012 Apr; 49(4):249-53. PubMed ID: 22499344
[TBL] [Abstract][Full Text] [Related]
15. Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell.
Groesser L; Herschberger E; Sagrera A; Shwayder T; Flux K; Ehmann L; Wollenberg A; Torrelo A; Bagazgoitia L; Diaz-Ley B; Tinschert S; Oschlies I; Singer S; Mickler M; Toll A; Landthaler M; Real FX; Hafner C
J Invest Dermatol; 2013 Aug; 133(8):1998-2003. PubMed ID: 23337891
[TBL] [Abstract][Full Text] [Related]
16. DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.
de Castro LF; Ovejero D; Boyce AM
Eur J Endocrinol; 2020 May; 182(5):R83-R99. PubMed ID: 32069220
[TBL] [Abstract][Full Text] [Related]
17. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.
Hafner C; van Oers JM; Vogt T; Landthaler M; Stoehr R; Blaszyk H; Hofstaedter F; Zwarthoff EC; Hartmann A
J Clin Invest; 2006 Aug; 116(8):2201-2207. PubMed ID: 16841094
[TBL] [Abstract][Full Text] [Related]
18. Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23: A case report.
Sato T; Muroya K; Asakura Y; Yachie A; Nishimura G; Aida N; Machida J; Tanaka Y; Hasegawa T; Adachi M
Am J Med Genet A; 2015 Oct; 167A(10):2430-4. PubMed ID: 26059403
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
20. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome.
Hoffman WH; Jueppner HW; Deyoung BR; O'dorisio MS; Given KS
Am J Med Genet A; 2005 Apr; 134(3):233-6. PubMed ID: 15742370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
